{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=31", "query": { "intervention": "Phase duration", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 3754, "total_pages": 376, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T05:51:55.784Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00861744", "title": "Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rubella", "Mumps", "Measles", "Measles-Mumps-Rubella Vaccine" ], "interventions": [ { "name": "GSK Biological's investigational vaccine 209762", "type": "BIOLOGICAL" }, { "name": "M-M-R® II (Merck and Co)", "type": "BIOLOGICAL" }, { "name": "Varivax®", "type": "BIOLOGICAL" }, { "name": "Havrix®", "type": "BIOLOGICAL" }, { "name": "Prevnar®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 1259, "start_date": "2009-06-03", "completion_date": "2012-06-18", "has_results": true, "last_update_posted_date": "2020-01-03", "last_synced_at": "2026-10-31T05:51:55.784Z", "location_count": 45, "location_summary": "Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Conway", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861744" }, { "nct_id": "NCT05292664", "title": "Venetoclax Basket Trial for High Risk Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndromes, de Novo", "Myelodysplastic Syndromes, Secondary", "Myelodysplastic Syndromes, Previously Treated", "Treatment-Related Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome", "Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphoblastic Leukemia With Failed Remission", "Lymphoblastic Lymphoma, in Relapse", "Lymphoblastic Lymphoma, Refractory", "Acute Leukemia of Ambiguous Lineage in Relapse", "Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Erwinia asparaginase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrew E. Place, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "40 Years", "sex": "ALL", "summary": "1 Year to 40 Years" }, "enrollment_count": 30, "start_date": "2023-03-29", "completion_date": "2030-07-02", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-10-31T05:51:55.784Z", "location_count": 5, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05292664" }, { "nct_id": "NCT02556463", "title": "A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "CTCL", "Cancer" ], "interventions": [ { "name": "MEDI9197", "type": "DRUG" }, { "name": "durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 53, "start_date": "2015-11-04", "completion_date": "2018-10-26", "has_results": false, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-10-31T05:51:55.784Z", "location_count": 8, "location_summary": "San Francisco, California • Aurora, Colorado • Minneapolis, Minnesota + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02556463" }, { "nct_id": "NCT01314014", "title": "Imexon for Relapsed Follicular and Aggressive Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma", "Lymphoplasmacytic Lymphoma", "Diffuse Large B Cell Lymphoma", "Mantle Cell Lymphoma", "Burkitt's Lymphoma" ], "interventions": [ { "name": "Imexon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-05", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2016-01-06", "last_synced_at": "2026-10-31T05:51:55.784Z", "location_count": 2, "location_summary": "Tucson, Arizona • Rochester, New York", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01314014" }, { "nct_id": "NCT07637578", "title": "A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma (MM)", "Multiple Myeloma Refractory", "Multiple Myeloma in Relapse", "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2026-09-01", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-31T05:51:55.784Z", "location_count": 6, "location_summary": "Denver, Colorado • Columbia, Maryland • Las Vegas, Nevada + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07637578" }, { "nct_id": "NCT03400826", "title": "Effects of Simvastatin on Uterine Leiomyoma Size", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibroid Uterus", "Fibroid Tumor", "Leiomyoma", "Fibromyoma", "Leiomyoma, Uterine" ], "interventions": [ { "name": "Simvastatin 40mg", "type": "DRUG" }, { "name": "Placebo 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 60, "start_date": "2018-08-20", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-31T05:51:55.784Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03400826" }, { "nct_id": "NCT00605826", "title": "A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Fecal Incontinence" ], "interventions": [ { "name": "NASHA/Dx (Solesta) Gel", "type": "DEVICE" }, { "name": "Sham Injection", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 206, "start_date": "2006-09-07", "completion_date": "2009-11-23", "has_results": true, "last_update_posted_date": "2020-08-18", "last_synced_at": "2026-10-31T05:51:55.784Z", "location_count": 8, "location_summary": "San Francisco, California • Tampa, Florida • Burlington, Massachusetts + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00605826" }, { "nct_id": "NCT07137338", "title": "A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dilated Cardiomyopathy (DCM)" ], "interventions": [ { "name": "RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Rocket Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 8, "start_date": "2026-04-17", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-31T05:51:55.784Z", "location_count": 3, "location_summary": "San Diego, California • Rochester, Minnesota • Charleston, South Carolina", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07137338" }, { "nct_id": "NCT03066778", "title": "A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer (SCLC)" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Normal saline solution", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 453, "start_date": "2017-05-02", "completion_date": "2021-09-21", "has_results": true, "last_update_posted_date": "2022-10-03", "last_synced_at": "2026-10-31T05:51:55.784Z", "location_count": 27, "location_summary": "Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Munster", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03066778" }, { "nct_id": "NCT03263091", "title": "Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)", "Anemia" ], "interventions": [ { "name": "Roxadustat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2018-01-29", "completion_date": "2023-06-20", "has_results": true, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-10-31T05:51:55.784Z", "location_count": 30, "location_summary": "Bakersfield, California • Beverly Hills, California • Burbank, California + 25 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Laguna Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03263091" } ] }